A Phase III, Double-blind, Randomized, Controlled Study to Evaluate Immunogenicity and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine, Administered Intramuscularly (0, 1, 6 Month Schedule) in Healthy Females Aged 18 - 35 Years
Phase of Trial: Phase III
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 12 Dec 2007 Status changed from in progress to completed.
- 14 Nov 2006 Status change
- 25 Oct 2006 New trial record.